It can therefore be assumed that long-term therapy with this commonly used drug will not have a harmful effect on antibacterial and anti-tumor immunity, and the specific outcomes of metformin therapy on mTOR signaling in macrophages have recently been reviewed in detail by Jafarzadeh and colleagues [173]. The gene discussed is MTOR; the disease is neoplasm.